Quinazolines as potent and highly selective PDE5 inhibitors as potential therapeutics for male erectile dysfunction

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 23, 2008, Pages 6279-6282

  Kim, Young Hoon ^a,d   Choi, Hojin ^a   Lee, Jaekwang ^a   Hwang, In Chang ^a   Moon, Seung Kee ^a   Kim, Soo Jin ^a   Lee, Hong Woo ^a   Im, Dai Sig ^a   Lee, Sung Sook ^a   Ahn, Soon Kil ^a   Kim, Sang Woong ^b   Han, Cheol Kyu ^c   Yoon, Jeong Hyeok ^c   Lee, Kyung Joo ^a   Choi, Nam Song ^a  

^a Chong Kun Dang Research Institute   (South Korea)

^b LeadGenex   (South Korea)

^c Equispharm Co Ltd   (South Korea)

^d Soongsil University   (South Korea)

Author keywords

Inhibitor; MED; PDE11; PDE5; PDE6; Quinazoline

Indexed keywords

4 (3 CHLORO 4 METHOXY)BENZYLAMINO 7 METHOXYQUINAZOLINE DERIVATIVE; PHOSPHODIESTERASE V INHIBITOR; QUINAZOLINE DERIVATIVE; SILDENAFIL; TADALAFIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; ERECTILE DYSFUNCTION; MALE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

COMBINATORIAL CHEMISTRY TECHNIQUES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; ERECTILE DYSFUNCTION; HUMANS; MALE; MOLECULAR STRUCTURE; PENILE ERECTION; PHOSPHODIESTERASE INHIBITORS; QUINAZOLINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 55749112653     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.09.108     Document Type: Article

References (32)

1. Martel A.M., Graul A., Rabasseda X., and Castaner R. Drugs Future 22 (1997) 138
2. Terret N.K., Bell A.S., Brown D., and Ellis P. Bioorg. Med. Chem. Lett. 6 (1996) 1819
3. Gibson A. Eur. J. Pharmacol. 411 (2001) 1
4. Andersson K.-E., and Wagner G. Physiol. Rev. 75 (1995) 191
5. Rotella D.P. Nat. Rev. Drug Discov. 1 (2002) 674
6. Manallack D.T., Hughes R.A., and Thompson P.E. J. Med. Chem. 48 (2005) 3449
7. Osterloh I.H., and Riley A. Br. J. Clin. Pharmacol. 53 (2002) 219
8. Beavo J.A. Physiol. Rev. 75 (1995) 725
9. Bischoff E. Int. J. Impot. Res. 16 (2004) S34
10. Daugan A., Grondin P., Ruault C., Coste H., Kirilovsky J., and Hyafil F. J. Med. Chem. 46 (2003) 4525
11. Porst H. EAU Update Ser. 2 (2004) 56
12. Makhlouf A., Kshirsagar A., and Niederberger C. Int. J. Impot. Res. 18 (2006) 501
13. Francis S.H. Int. J. Impot. Res. 17 (2005) 467
14. Seftel A.D. J. Urol. 174 (2005) 1043
15. Giovannoni M.P., Vergelli C., Biancalani C., Cesari N., Graziano A., Biagini P., Gracia J., Gavalda A., and Dal Piaz V. J. Med. Chem. 49 (2006) 5363
16. Jiang W., Guan J., Macielag M.J., Zhang S., Kraft Y., John T.M., H.-J. D., Lunden S., and Sui Z. J. Med. Chem. 48 (2005) 2126
17. Haning H., Niewoehner U., Schenke T., Lampe T., Hillish A., and Bischoff E. Bioorg. Med. Chem. Lett. 15 (2005) 3900
18. Xia G., Li J., Peng A., Lai S., Zhang S., Shen J., Liu Z., Chen X., and Ji R. Bioorg. Med. Chem. Lett. 15 (2005) 2790
19. Bi Y., Stoy P., Ada L., He B., Krupinski J., Normandin D., Pongrac R., Seliger L., Watson A., and Macor J. Bioorg. Med. Chem. Lett. 14 (2004) 1577
20. Watanabe N., Kabasawa Y., Takase Y., Matsukura M., Miyazaki K., Ishihara H., Kodama K., and Adachi H. J. Med. Chem. 41 (1998) 3367
21. Arnold N.J., Beer D., Bhalay G., Craig S., Farr D., Glen A., Hatto J.D., Jones D., Moser H.E., Naef R., Turner K.L., Tweed M.F., Watson S.J., and Zurini M. Bioorg. Med. Chem. Lett. 17 (2007) 2376
22. Vieth M., Sutherland J.J., Robertson D.H., and Campbell R.M. Drug Discov. Today 10 (2005) 839
23. Scapin G. Drug Discov. Today 7 (2002) 601
24. Takase Y., Saeki T., Watanabe N., Adachi H., Souda S., and Saito I. J. Med. Chem. 37 (1994) 2106
25. PDE5 assays were carried out as described in:. Turko I.V., Ballard S.A., Francis S.H., and Corbin J.D. Mol. Pharm. 56 (1999) 124 Assays for other isozymes were conducted in a similar manner.
26. Rotella D.P., Sun Z., Zhu Y., Krupinski J., Pongrac R., Sliger L., Normandin D., and Macor J.E. J. Med. Chem. 43 (2000) 5037
27. Bi Y., Stoy P., Adam L., He B., Krupinski J., Mormandin D., Pongrac R., Seliger L., Watson A., and Macor J.E. Bioorg. Med. Chem. Lett. 11 (2001) 2461
28. 3OD) δ 8.50 (s, 1H), 8.41 (s, 1H), 7.38 (d, J = 2.0 Hz, 1H), 7.28 (dd, J = 8.5, 2.0 Hz, 1H), 6.98 (d, J = 8.5 Hz, 1H), 4.73 (s, 2H), 3.89-3.81 (m, 8H), 3.35 (t, J = 6.9 Hz, 2H), 2.54 (q, J = 7.6 Hz, 2H), 1.25 (t, J = 7.6 Hz, 3H); MS (ESI) m/z 445 (M+H).
29. Bischoff E., Niewoehner U., Haning H., Es Sayed M., Schenke T., and Schlemmer K.H. J. Urol. 165 (2001) 1315
30. Kang, K. K.; Ahn, G. J.; Ahn, B. O.; Yoo, M.; Kim, W. B. Eur. Urol. 2003, 43, 689. In brief, New Zealand white rabbits weighing 3-4 kg (n = 4) were orally dosed (dissolved in distilled water) with compounds, followed by injection of SNP (0.1 mg/0.1 ml/kg, dissolved in saline) after 60 min, and the length of penis (covered + mucosa area) was measured with sliding calipers, recorded in cm for total 2 or 2.5 h after administration of test compounds.
31. Enzyme sources: PDE1, bovine heart; PDE2, bovine heart; PDE3, bovine platelet; PDE5, bovine platelet; PDE6, bovine retina; and PDE11, human recombinant.
32. Artursson P., and Tavelin S. In: Waterbeemd H., Lennernas H., and Artursson P. (Eds). Drug Bioavailability Vol. 18 (2003), Wiley-VCH 72-89 (Methods and Principles in Medicinal Chemistry series)